NurExone Biologic
Haifa, Israel · Biotechnology
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
Key facts
- Headquarters
- Haifa, Israel
- Employees
- 25
- Industries
- Biotechnology
- Status
- Private
- Website
- nurexone.com
- Company page
Recent activity at NurExone Biologic
- : NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes. (date Fundz recorded it)
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic
- : NurExone Biologic Inc. Announces Acquisition of Master Cell Bank to Enhance Exosome-Based Therapies.
- : NurExone Announces Transfer of Manufacturing of ExoPTEN Drug to GMP Manufacturer (date Fundz recorded it)
- : NurExone Biologic
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
NurExone Biologic funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $450K |
| Jun 2026 | Venture | $442K |
| Mar 2026 | Venture | $280K |
| Aug 2025 | Venture | $148K |
| Apr 2025 | Venture | $1.6M |
Leadership
- Limor Chen, Head of Scientific Collaborations & External Partnerships
- Oded Orgil, Director
- Yoram Drucker, Director
- Gadi Riesenfeld, Director
- Eran Ovadya, Executive Officer
- Lior Shaltiel, Director
Verified email and direct lines for NurExone Biologic’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
NurExone Biologic in the news
- NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results - GlobeNewswire (Oct 09, 2026)
- A next-generation therapeutic approach for patients after spinal cord injuries - Nature (Oct 11, 2023)
- NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - Yahoo Finance (Aug 28, 2026)
- NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment - BioInformant (Nov 07, 2023)
- NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing - Yahoo Finance (Sep 02, 2026)
- NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process - BioInformant (Aug 31, 2024)
- NurExone Reports New Preclinical Tissue-Analysis Data - GlobeNewswire (Aug 14, 2026)
- NurExone Biologic Inc. (NRX.V) Stock Price, News, Quote & History - Yahoo Finance (Jun 17, 2020)
Companies similar to NurExone Biologic
- Northwest Biotherapeutics · Biotechnology
- Nanopath · Biotechnology
- Navigator Medicines · Biotechnology
- Mithril Medicine · Biotechnology
- Tenpoint Therapeutics · Biotechnology
About NurExone Biologic: questions and answers
What does NurExone Biologic do?
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
Where is NurExone Biologic headquartered?
NurExone Biologic is headquartered in Haifa, Israel.
How many employees does NurExone Biologic have?
NurExone Biologic has about 25 employees.
Has NurExone Biologic raised funding?
Yes. Fundz has recorded 5 funding events for NurExone Biologic. The most recent, Post-IPO Equity of $450K, was in Aug 2026.
What is the latest news on NurExone Biologic?
On Aug 22, 2026, NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy